登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603087 证券简称：甘李药业 公告编号：2025-055 甘李药业股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ （二）本次权益变动时间及方式 ● 本次权益变动后，信息披露义务人北京旭特宏达科技有限公司（以下简称"旭特宏达"）及其一致行动 人甘忠如先生合计持有公司股份比例从42.60%减少至40.00%。 一、本次权益变动基本情况 公司于2025年7月29日，收到信息披露义务人旭特宏达的书面通知和《简式权益变动报告书》。现将有 关权益变动情况公告如下： （一）信息披露义务人基本情况 1、北京旭特宏达科技有限公司 ■ 2、甘忠如 ● 本次权益变动属于主动减持和被动稀释，不触及要约收购。 ● 本次权益变动不会导致甘李药业股份有限公司（以下简称"公司"）控股股东及实际控制人发生变化。 本次权益变动前，信息披露义务人旭特宏达及其一致行动人甘忠如先生合计持有公司股份数量为 253,138,194股，占当时公司总 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-055 （二）本次权益变动时间及方式 本次权益变动前，信息披露义务人旭特宏达及其一致行动人甘忠如先生合计 持有公司股份数量为 253,138,194 股，占当时公司总股本的持股比例为 42.60%。 旭特宏达自 2024 年 5 月 24 日至 2025 年 7 月 29 日期间，因公司总股本增加被动 稀释，总股份减少被动增加及其通过集中竞价方式减持公司股份 12,712,002 股， 导致权益变动比例约为 2.20%，甘忠如先生因公司总股本增加被动稀释，总股份 减少被动增加，导致权益变动比例约为 0.40%。 本次权益变动后旭特宏达及其一致行动人甘忠如先生合计持有公司股份数 量为 240,426,192 股，占公司当前总股本比例为 40.00%。 公司于 2025 年 7 月 29 日，收到信息披露义务人旭特宏达的书面通知和《简 式权益变动报告书》。现将有关权益变动情况公告如下： 咨询。(市场主体依法自主选择经营项目，开展经营活动;依法须经 经营范围 | | 批准的项目，经相关部门批准后依批准的内容开展经营活动;不得 | | --- | --- ...

甘李药业股份有限公司简式权益变动报告书 甘李药业股份有限公司 甘李药业股份有限公司简式权益变动报告书 上市公司名称：甘李药业股份有限公司 股票上市地点：上海证券交易所 股票简称：甘李药业 股票代码：603087 信息披露义务人 1：北京旭特宏达科技有限公司 住所及通讯地址：北京市通州区南凤西一路 205 号院 2 号楼 2 层 信息披露义务人 2：甘忠如 住所及通讯地址：北京市朝阳区*** 权益变动性质：股份减少，权益变动触及 5%整数倍刻度 签署日期：二〇二五年七月二十九日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号 ——权益变动报告书》等相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报告 书已全面披露信息披露义务人在甘李药业拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-055 甘李药业股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次权益变动基本情况 公司于 2025 年 7 月 29 日，收到信息披露义务人旭特宏达的书面通知和《简 式权益变动报告书》。现将有关权益变动情况公告如下： （一）信息披露义务人基本情况 1、北京旭特宏达科技有限公司 | 公司名称 | 北京旭特宏达科技有限公司 | | --- | --- | | 注册地址 | 北京市通州区南凤西一路 205 号院 2 号楼 2 层 | | 法定代表人 | 甘忠如 | | 注册资本 | 万元 701.1955 | | 统一社会信用代码 | 91110112565832509N | | 企业类型 | 有限责任公司(自然人投资或控股) | | 姓名 | 甘忠如 | | --- | --- | | 性别 | 男 | | 国籍 | 中国 | | 身份证件号码 | 110108************ | | 住所 ...

甘李药业股份有限公司简式权益变动报告书 甘李药业股份有限公司 简式权益变动报告书 上市公司名称：甘李药业股份有限公司 股票上市地点：上海证券交易所 股票简称：甘李药业 股票代码：603087 信息披露义务人 1：北京旭特宏达科技有限公司 住所及通讯地址：北京市通州区南凤西一路 205 号院 2 号楼 2 层 信息披露义务人 2：甘忠如 住所及通讯地址：北京市朝阳区*** 权益变动性质：股份减少，权益变动触及 5%整数倍刻度 签署日期：二〇二五年七月二十九日 1 甘李药业股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号 ——权益变动报告书》等相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报告 书已全面披露信息披露义务人在甘李药业拥有权益的股份变动情况。 截至本报告书 ...

Core Insights - Multiple domestic GLP-1 weight loss drug developers are targeting overseas markets and have established several licensing agreements with multinational companies, indicating that competition for Chinese GLP-1 weight loss drugs will extend to the global market [1][5] - The U.S. market, known for its strong payment capabilities, is becoming a key focus for Chinese weight loss drug companies as they accelerate their research and development efforts [1][6] Industry Developments - Companies such as Heng Rui Medicine, Cheng Yi Biology, East China Medicine, Gan Li Pharmaceutical, and Hansoh Pharmaceutical have entered the GLP-1 weight loss drug market, including next-generation oral small molecule drugs [1] - Recent breakthroughs include the approval of the dual receptor agonist Masitide injection by the National Medical Products Administration (NMPA) for long-term weight control in adults, marking it as the only domestic GLP-1 weight loss drug competing with international giants [3][5] Clinical Progress - Several companies have reported positive clinical data, with Heng Rui Medicine and its U.S. partner Kailera Therapeutics announcing successful Phase III trial results for their GLP-1/GIP dual receptor agonist HRS9531, with plans to submit a New Drug Application (NDA) [4] - The drug Ecnoglutide developed by Xianweida has submitted an NDA for weight management and type 2 diabetes indications, although it has not yet been approved [4][6] Market Potential - The global GLP-1 drug market is projected to exceed $60 billion by 2025, with the Chinese market expected to reach 20 billion RMB, growing at over 28% annually [6] - The U.S. market presents significant opportunities, with high profit margins for weight loss drugs, despite the current dominance of two major players, Eli Lilly and Novo Nordisk [6][7] Patient Engagement - A recent survey indicated that 63% of U.S. patients continued using the weight loss drug Semaglutide after one year, highlighting the growing acceptance and adherence to GLP-1 medications [7] - The expansion of insurance coverage for these drugs is expected to further increase the patient population eligible for GLP-1 weight loss treatments [7]

Summary of Key Points Core Viewpoint - On July 25, 2025, a total of 8 stocks in the A-share market will face the lifting of restrictions on share sales, with a total of 1.872 billion shares being unlocked, amounting to a market value of 50.111 billion yuan based on the previous trading day's closing price [1]. Group 1: Stock Unlocking Details - The top three stocks by the number of shares unlocked are: - Daqian Energy (688303) with 1.593 billion shares [1][2] - Jintuo Co., Ltd. (603211) with 204 million shares [1][2] - Wanlang Magnetic Plastic (603150) with 31.966 million shares [1][2] Group 2: Market Value of Unlocked Shares - The top three stocks by market value of unlocked shares are: - Daqian Energy (688303) with a market value of 43.921 billion yuan [1][2] - Jintuo Co., Ltd. (603211) with a market value of 3.692 billion yuan [1][2] - Wanlang Magnetic Plastic (603150) with a market value of 1.066 billion yuan [1][2]

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: The conference call primarily discusses the healthcare sector in China, particularly the medical technology (Medtech), in vitro diagnostics (IVD), retail pharmacies, hospitals, vaccines, and insulin markets [1][2]. Core Insights and Arguments Medtech - **Key Areas of Focus**: 1. Progress of capital equipment value-based procurement (VBP) and the trade-in policy [1] 2. Channel destocking trends [1] 3. Import substitution trends post-VBP, including intraocular lenses (IOLs) and IVD [1] - **VBP Impact**: The June bidding value data showed a year-on-year growth rate of 49%, but a month-on-month decline of 3%, indicating lower unit prices due to VBP [10]. IVD Market - **Weak Demand**: The IVD sector continues to face challenges, with a projected 20% year-on-year decline in the CLIA reagent market size for 2025 [19]. - **AmoyDx Performance**: AmoyDx is expected to grow against the trend due to its strong presence in compliant in-hospital sales channels, benefiting from the anti-corruption campaign [21]. Insulin Market - **Domestic Substitution**: The insulin industry has seen significant growth, particularly for insulin analogs from companies like Gan & Lee and THDB, which reported rapid revenue growth in 1Q25 [22]. Retail Pharmacies - **Market Pressure**: Retail pharmacies are under pressure due to strict reimbursement policies and weak consumer spending. However, there is a potential market-clearing trend expected by year-end [31]. Hospitals - **New Product Feedback**: Hospitals are seeing new product introductions, such as the new version of SMILE surgery and new PIOL products, which are expected to drive consumption recovery [1]. Vaccine Market - **Anti-Corruption Campaign**: The ongoing anti-corruption campaign within the CDC system is impacting vaccine demand and distribution channels [1]. Financial Performance and Estimates Earnings Revisions - **Mindray**: Annual earnings estimates revised down by 2.1% to 5.0% for 2025E-27E due to industry headwinds in medical equipment and IVD [2][37]. - **United Imaging**: Revenue and earnings forecasts adjusted down to reflect lower-than-expected bidding data [39]. - **SNIBE**: Earnings estimates revised down by 1.4% to 7.1% for 2025E-27E due to policy headwinds in the IVD sector [40]. Revenue Growth Expectations - **High Growth Companies**: THDB and Gan & Lee are expected to achieve the highest revenue growth due to a low base from VBP renewal in 2Q24 [6]. - **Mindray's Decline**: Mindray's China business is expected to decline by 26% year-on-year in 2Q25 due to IVD weakness [9]. Other Important Insights - **Trade-in Policy Concerns**: The trade-in stimulus fund is expected to run out, leading to a decline in applications and a reduced stimulus effect in the second half of 2025 [10]. - **Market Dynamics**: The healthcare market is experiencing a shift with increasing government support for procurement and a focus on innovative products [47][48]. Conclusion - The healthcare sector in China is facing various challenges, including policy headwinds, weak demand in certain segments, and the impact of ongoing reforms. However, there are also opportunities for growth, particularly in innovative products and domestic substitution trends. Companies like AmoyDx, Gan & Lee, and THDB are positioned to benefit from these trends, while others like Mindray and SNIBE are facing headwinds that may impact their performance in the near term.

Core Viewpoint - The Chinese innovative drug industry is experiencing significant growth in the first half of 2025, driven by policy benefits and international breakthroughs, with leading companies achieving explosive growth due to technological barriers and commercialization capabilities [1]. Company Performance Summaries - **Shuanglu Pharmaceutical**: Expected net profit for H1 2025 is between 100 million and 135 million RMB, a year-on-year increase of 237.95% to 356.24% from 29.59 million RMB in the same period last year, primarily benefiting from financial asset returns and breakthroughs in innovative drug pipelines [3][4]. - **Sino Biopharmaceutical**: Anticipated net profit ranges from 77.03 million to 94.14 million RMB, reflecting a year-on-year increase of 253.54% to 332.10%, driven by strong performance in peptide raw material exports [5][7]. - **Microchip Biotech**: Expected net profit of approximately 30.06 million RMB, representing a 173% increase, attributed to the inclusion of its core product (Sida Benamine) in medical insurance and optimized sales strategies [8][10]. - **Buchang Pharmaceutical**: Projected net profit between 488 million and 708 million RMB, a year-on-year increase of 110.88% to 205.94%, due to increased sales scale and reduced production costs [11][13]. - **Ganli Pharmaceutical**: Expected net profit of 600 million to 640 million RMB, a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [15][16]. - **Shanghai Pharmaceuticals**: Anticipated net profit of 4.45 billion RMB, an increase of approximately 52% from the previous year, following the acquisition of a 10% stake in Shanghai Hengrui Medicine [17][18]. - **Liaoning Chengda**: Expected net profit between 689 million and 735 million RMB, a year-on-year increase of 50% to 60%, supported by a dual-driven strategy of healthcare and financial investment [19][21]. - **WuXi AppTec**: Projected net profit of approximately 6.3 billion RMB, a year-on-year increase of about 44.43%, driven by optimized CRDMO business models and significant non-operating gains from stock sales [23][25]. - **Notai Biopharmaceutical**: Expected net profit between 300 million and 330 million RMB, a year-on-year increase of 32.06% to 45.27%, attributed to sales growth in peptide raw materials [27][29]. - **I-Wu Biotech**: Anticipated net profit between 170 million and 180 million RMB, reflecting a year-on-year increase of 13.92% to 23.97%, focusing on allergy disease treatment products [30][31]. Industry Trends - The performance divergence in the innovative drug industry in 2025 indicates a shift from "scale competition" to "technological competition," with companies possessing genuine innovation capabilities and international layouts expected to lead, while those relying on capital operations or policy arbitrage face growth challenges [32].

Group 1 - The company held its fifth supervisory board's second meeting on July 21, 2025, with a valid resolution passed by the attending supervisors [1] - The supervisory board unanimously approved the proposal to continue using idle raised funds for cash management, allowing up to RMB 250 million for investment in safe and liquid financial products [1] - The investment products include time deposits, structured deposits, and large certificates of deposit, with a usage period not exceeding 12 months from the date of approval [1][2] Group 2 - The board's decision ensures that the use of idle funds will not affect the normal progress of the fundraising investment plan [1] - The voting results showed 3 votes in favor, with no opposition or abstentions [2]